Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Passage Bio's PBGM-01?
PBGM-01 is a gene therapy commercialized by Passage Bio, with a leading Phase II program in GM1 Gangliosidosis (Beta Galactosidase...
Data Insights
Risk adjusted net present value: What is the current valuation of Passage Bio's PBGM-01?
PBGM-01 is a gene therapy commercialized by Passage Bio, with a leading Phase II program in GM1 Gangliosidosis (Beta Galactosidase...